AzTrials
AzTrials

Myelodysplastic Syndrome (MDS)Phase 2NCT02793544

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

A Phase 2 study testing Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 and Total Body Irradiation (TBI) 200cGy on Day -1 in people with Myelodysplastic Syndrome (MDS) and Chronic Lymphocytic Leukemia (CLL), run by Center for International Blood and Marrow Transplant Research at 11 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF) for graft versus host disease (GVHD)… Read more about this study

Who is it for?
Ages 15 to 70 years
What is being tested?
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 and Total Body Irradiation (TBI) 200cGy on Day -1
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
11 sitesUnited States
Study dates
Dec 2016to Mar 2020
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 70 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Age ≥ 15 years and < 71 years at the time of signing the informed consent form
  • Partially HLA-mismatched unrelated donor: HLA typing will be performed at high resolution (allele level) for the HLA-A, -B, -C, and -DRB1 loci; a minimum match of 4/8 at HLA-A, -B, -C, and -DRB1 is required
  • Product planned for infusion is bone marrow
  • Disease and disease status:
  • Acute Leukemias or T lymphoblastic lymphoma in 1st or subsequent complete remission (CR): Acute lymphoblastic leukemia (ALL)/T lymphoblastic lymphoma; acute myelogenous leukemia (AML); acute biphenotypic leukemia (ABL); acute undifferentiated leukemia (AUL)
  • Myelodysplastic Syndrome (MDS), fulfilling the following criteria: Subjects with de novo MDS who have or have previously had Intermediate-2 or High risk disease as determined by the International Prognostic Scoring System (IPSS). Current Intermediate-2 or High risk disease is not a requirement; Subjects must have < 20% bone marrow blasts, assessed within 60 days of informed consent; Subjects may have received prior therapy for the treatment of MDS prior to enrollment
Show all 20Show fewer
  • Chronic Lymphocytic Leukemia (CLL) in CR if RIC is to be used; in CR or partial response (PR) if FIC is to be used
  • Chronic myeloid leukemia (CML) in 1st or subsequent chronic phase characterized by <10% blasts in the blood or bone marrow.
  • Chemotherapy-sensitive lymphoma in status other than 1st CR
  • Performance status: Karnofsky or Lansky score ≥ 60% (Appendix A)
  • Adequate organ function defined as:
  • Cardiac: left ventricular ejection fraction (LVEF) at rest ≥ 35% (RIC cohort) or LVEF at rest ≥ 40% (FIC cohort), or left ventricular shortening fraction (LVFS) ≥ 25%
  • Pulmonary: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume (FEV1), forced vital capacity (FVC) ≥ 50% predicted by pulmonary function tests (PFTs)
  • Hepatic: total bilirubin ≤ 2.5 mg/dL, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) < 5 x upper limit of (ULN) (unless disease related)
  • Renal: serum creatinine (SCr) within normal range for age (see table 2.3). If SCr is outside normal range for age, creatinine clearance (CrCl) > 40 mL/min/1.73m2 must be obtained (measured by 24-hour (hr) urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR (by Cockcroft-Gault formula for those aged ≥ 18 years; by Original Schwartz estimate for those < 18 years))
  • Subjects ≥ 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for subjects < 18 years of age. Pediatric subjects will be included in age appropriate discussion in order to obtain assent.
  • Subjects with documentation of confirmed HIV-1 infection (i.e. HIV-positive), and a hematologic malignancy who meets all other eligibility requirements must:
  • Receive only RIC regimen (i.e. Regimen A)
  • Be willing to comply with effective antiretroviral therapy (ARV)
  • Have achieved a sustained virologic response for 12 weeks after cessation of hepatitis C antiviral treatment (in HIV-positive subjects with hepatitis C)

Who cannot join

  • HLA-matched related or 8/8 allele matched (HLA-A, -B, -C, -DRB1) unrelated donor available. This exclusion does not apply to HIV-positive subjects who have a CCR5delta32 homozygous donor.
  • Autologous HCT < 3 months prior to the time of signing the informed consent form
  • Females who are breast-feeding or pregnant
  • HIV-positive subjects:
  • Acquired immunodeficiency syndrome (AIDS) related syndromes or symptoms that may pose an excessive risk for transplantation-related morbidity as determined by the Treatment Review Committee (see Appendix D).
  • Untreatable HIV infection due to multidrug ARV resistance. Subjects with a detectable or standard viral load > 750 copies/mL should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the ARV review (described in Appendix D).
Show all 11Show fewer
  • May not be currently prescribed ritonavir, cobacistat and/or zidovudine
  • Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)
  • Prior allogeneic HCT
  • History of primary idiopathic myelofibrosis
  • MDS subjects may not receive RIC and must be < 50 years of age at the time of signing the informed consent form

Trial locations and contacts

11 sites in 1 country.

11 sites in 1 country

United States11 sites

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland, 21201

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21287

  • University of North Carolina Hospitals

    Chapel Hill, North Carolina, 27599

  • Ohio State Medical Center, James Cancer Center

    Columbus, Ohio, 43210

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201

  • Shands HealthCare & University of Florida

    Gainesville, Florida, 32610

  • University of Miami

    Miami, Florida, 33136

  • Froedtert Memorial Lutheran Hospital

    Milwaukee, Wisconsin, 53226

  • Memorial Sloan Kettering Cancer Center - Adults

    New York, New York, 10065

  • Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program

    Richmond, Virginia, 23298

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612

Other trials in United States

About this study

Official title: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies

This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF) for graft versus host disease (GVHD) prophylaxis in patients with hematologic malignancies.

Being tested
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan
Medical subject headings
Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Leukemia, Biphenotypic, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FludarabineDrug

    Also called Fludara®

    • Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).
    • The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).
    • creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted.

  • Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5Drug

    Also called Cytoxan®

    • Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.
    • Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
    • Hydration prior to Cy may be given according to institutional guideline.
    • Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.

  • Total Body Irradiation (TBI) 200cGy on Day -1Radiation

    • 200 cGy TBI is administered in a single fraction on Day -1.
    • Radiation sources, dose rates, and shielding follow institutional practice.

  • Infusion of non-T-cell depleted bone marrow on Day 0Procedure or surgery

    • On Day 0, the harvested bone marrow is infused.
    • Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.
    • The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight.

  • BusulfanDrug

    Also called Busulfex®

    • Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM*min (Perkins et al., 2012))
    • Busulfan dosing is based on adjusted IBW (Appendix K)

  • Cyclophosphamide 50mg/kg/day IV on Days -2,-1Drug

    Also called Cytoxan®

    • Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.
    • Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
    • Hydration prior to Cy may be given according to institutional guideline.
    • Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.

  • Cyclophosphamide 50mg/kg/day IV on Days -5,-4Drug

    Also called Cytoxan®

    • Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.
    • Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
    • Hydration prior to Cy may be given according to institutional guideline.
    • Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.

  • Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1Radiation

    • 200cGy TBI is administered in twice daily on Days -3, -2, and -1.
    • Radiation sources, dose rates, and shielding follow institutional practice.

  • Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4Drug

    • Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).
    • Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.
    • Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
    • Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight.

  • SirolimusDrug

    Also called rapamycin, Rapamune®

    • Sirolimus dosing is based on adjusted IBW (Appendix K).
    • Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.

    For subjects ≥ 18 years old:

    • A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.
    • Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.

    For subjects < 18 years old:

    • A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.
    • Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay.

  • Mycophenolate mofetilDrug

    Also called MMF, Cellcept®

    MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).

    An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD.

  • G-CSFDrug

    Also called filgrastim

    Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.

    Additional G-CSF may be administered as warranted.

  • Pre-HCT Mesna on Days -6 and -5Drug

    Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.

    Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.

  • Pre-HCT Mesna on Days -2 and -1Drug

    Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.

    Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.

  • Pre-HCT Mesna on Days -5 and -4Drug

    Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.

    Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.

  • Post-HCT MesnaDrug

    Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.

    Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight.

Study groups in NCT02793544
Study groupRoleWhat they receive
Regimen A (RIC: Flu/Cy/TBI)Active comparator1. Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2 2. Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 3. Total Body Irradiation (TBI) 200cGy on Day -1 4. Infusion of non-T-cell depleted bone marrow on Day 0 Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.
Receives: Drug: Fludarabine; Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5; Radiation: Total Body Irradiation (TBI) 200cGy on Day -1; Procedure: Infusion of non-T-cell depleted bone marrow on Day 0; Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4; Drug: Sirolimus; Drug: Mycophenolate mofetil; Drug: G-CSF; Drug: Pre-HCT Mesna on Days -6 and -5; Drug: Post-HCT Mesna
Regimen B 2a (FIC: Bu/Cy)Active comparator1. Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO) 2. Cyclophosphamide 50mg/kg/day IV on Days -2,-1 3. Infusion of non-T-cell depleted bone marrow on Day 0 Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.
Receives: Procedure: Infusion of non-T-cell depleted bone marrow on Day 0; Drug: Busulfan; Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1; Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4; Drug: Sirolimus; Drug: Mycophenolate mofetil; Drug: G-CSF; Drug: Pre-HCT Mesna on Days -2 and -1; Drug: Post-HCT Mesna
Regimen B 2b (FIC: Bu/Flu)Active comparator1. Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO) 2. Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2 3. Infusion of non-T-cell depleted bone marrow on Day 0 Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.
Receives: Drug: Fludarabine; Procedure: Infusion of non-T-cell depleted bone marrow on Day 0; Drug: Busulfan; Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4; Drug: Sirolimus; Drug: Mycophenolate mofetil; Drug: G-CSF; Drug: Post-HCT Mesna
Regimen C (FIC: Cy/TBI)Active comparator1. Cyclophosphamide 50mg/kg/day IV on Days -5,-4 2. Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1 3. Infusion of non-T-cell depleted bone marrow on Day 0 Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.
Receives: Procedure: Infusion of non-T-cell depleted bone marrow on Day 0; Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4; Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1; Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4; Drug: Sirolimus; Drug: Mycophenolate mofetil; Drug: G-CSF; Drug: Pre-HCT Mesna on Days -5 and -4; Drug: Post-HCT Mesna

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Survival

    Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first).

    The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 365 days post transplant

Secondary outcomes (31)

  1. Progression-free Survival

    Time from HCT until the documentation of disease progression / relapse or death due to any cause, whichever occurs first. Progression-free survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 180 days and 365 days post-transplant

  2. Transplant-related Mortality

    Death without evidence of disease progression or recurrence. A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days, 180 days, and 365 days post-transplant

  3. Cumulative Incidence of Neutrophil Recovery

    Achieving a donor derived ANC ≥ 500/mm3 for 3 consecutive laboratory values on different days. A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days and 365 days post transplant

  4. Cumulative Incidence of Platelet Recovery

    Achieving a platelet count ≥ 20,000/μL for 3 consecutive laboratory values on different days (with no platelet transfusions in the preceding seven days). A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days and 365 days post transplant

  5. Cumulative Incidence of Acute GVHD

    Any skin, gastrointestinal or liver abnormalities fulfilling the BMT CTN Manual of Operations (2013) criteria of grades II-IV acute GVHD. A cumulative incidence will be computed along with a 90% CI.

    Any skin, gastrointestinal or liver abnormalities fulfilling the BMT CTN Manual of Operations (2013) criteria of grades III-IV acute GVHD. A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days post-transplant

  6. Grades II-IV Acute GVHD

    Any skin, gastrointestinal or liver abnormalities fulfilling the BMT CTN Manual of Operations (2013) criteria of grades II-IV acute GVHD. A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days

  7. Grades III-IV Acute GVHD

    Any skin, gastrointestinal or liver abnormalities fulfilling the BMT CTN Manual of Operations (2013) criteria of grades III-IV acute GVHD. A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days

  8. Cumulative Incidence of Chronic GVHD

    Per National Institutes of Health (NIH) Consensus Criteria and includes organ involvement and severity, and overall global composite score (mild/moderate/severe). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first).

    The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 180 days and 365 days post-transplant

  9. Cumulative Incidences of Viral Reactivations and Infections: Grade 2-3 CMV Reactivation or Infection

    Grade 2: Clinically active CMV infection (e.g. symptoms, cytopenias) or CMV Viremia not decreasing by at least 2/3 of the baseline value after 2 weeks of therapy; Grade 3: CMV end-organ involvement (pneumonitis, enteritis, retinitis). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first).

    The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 100 days, 180 days, and 365 days

  10. Cumulative Incidences of Viral Reactivations and Infections: Grade 3 CMV Infection

    CMV end-organ involvement (pneumonitis, enteritis, retinitis) ). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 100 days, 180 days, and 365 days

  11. Cumulative Incidences of Viral Reactivations and Infections: Grade 2-3 EBV Infection

    Grade 2: EBV reactivation requiring institution of therapy with rituximab; Grade 3: EBV post-transplant lymphoproliferative disorder). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 100 days, 180 days, and 365 days

  12. Cumulative Incidences of Viral Reactivations and Infections: Grade 2 BK Virus Infection

    BK viremia or viruria with clinical consequence requiring prolonged therapy and/or surgical intervention). A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days, 180 days, 365 days

  13. Cumulative Incidences of Viral Reactivations and Infections: Grade 2-3 Adenovirus Infection

    Grade 2: Adenoviral URI, viremia, or symptomatic viruria requiring treatment; Grade 3: ADV with end-organ involvement (except conjunctivitis and upper respiratory tract) ). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 100 days, 180 days, and 365 days

  14. Cumulative Incidences of Viral Reactivations and Infections: Grade 2 HHV-6 Infection

    Clinically active HHV-6 infection (e.g. symptoms, cytopenias) or HHV-6 viremia without viral load decline 0.5 log after 2 weeks of therapy). A cumulative incidence will be computed along with a 90% CI.

    Measured: 100 days, 180 days, 365 days

  15. Cumulative Incidence of Relapse/Progression

    Defined by either morphological, cytogenetic/molecular or radiological evidence of disease consistent with pre-HCT features. A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.

    Measured: 180 days and 365 days post-transplant

  16. Cumulative Incidences of Thrombotic Microangiopathy (TMA) and Hepatic Veno-occlusive Disease (VOD)/Sinusoidal Obstruction Syndrome (SOS)

    TMA is defined as (Ho et al., 2005):

    1. RBC fragmentation and >2 schistocytes per high-power field on peripheral smear
    2. Concurrent increased serum LDH above institutional baseline
    3. Concurrent renal and/or neurologic dysfunction without other explanation
    4. Negative direct and indirect Coombs test results A cumulative incidence will be computed along with a 90% CI.

    VOD/SOS is defined as: In the first 20 days after HCT, the presence of ≥2 of the following: 1. Bilirubin >2 mg/Dl, 2. Hepatomegaly or pain in right upper quadrant, 3. Weight gain (>2% basal weight).

    A cumulative incidence will be computed along with a 90% CI.

    Measured: 365 days post transplant

  17. Cumulative Incidence of Primary Graft Failure

    Lack of donor-derived neutrophil engraftment. The frequency of subjects experiencing primary graft failure by 56 days will be described.

    Measured: 56 days post-transplant

  18. Donor Chimerism

    Peripheral blood chimerism (% of donor chimerism) in whole blood (unsorted). The degree of donor chimerism will be summarized using descriptive statistics.

    Measured: 28 days, 56 days, 100 days, 180 days, and 365 days post-transplant

  19. Peripheral Blood Chimerism

    The frequency of subjects with Peripheral blood (unsorted) chimerism>95% at 56 days will be described.

    Measured: 56 days post-transplant

  20. Proportion of Subjects Proceeding to Transplant

    The proportion of subjects proceeding to HCT after informed consent.

    Measured: Pre-HCT

  21. Time From Search to Donor Identification

    Time from search to donor identification Time from preliminary search to formal donor activation.

    Measured: Pre-HCT

  22. Donor Selection Characteristics: HLA Match

    Number of matched donor and recipient HLA allele pairs. A matched donor would have 8/8 HLA allele pairs matching; mismatched donors listed below have one to four mismatched HLA allele pairs at HLA-A, -B, -C, or -DRB1.

    Measured: Pre-HCT

  23. Donor Selection Characteristics: Donor Age

    Donor age

    Measured: Pre-HCT

  24. Donor Selection Characteristics: Donor Age, Categorical

    Donor age, categorical

    Measured: Pre-HCT

  25. Donor Selection Characteristics: Donor Weight

    Donor weight

    Measured: Pre-HCT

  26. Donor Selection Characteristics: Donor Sex

    Donor sex

    Measured: Pre-HCT

  27. Donor Selection Characteristics: Donor and Recipient Sex

    Donor-recipient sex match

    Measured: Pre-HCT

  28. Donor Selection Characteristics: Donor and Recipient CMV Serostatus

    Donor-recipient Cytomegalovirus (CMV) serostatus match

    Measured: Pre-HCT

  29. Donor Selection Characteristics: Donor and Recipient ABO Blood Match

    Donor-recipient ABO group match

    Measured: Pre-HCT

  30. Donor Clonal Hematopoiesis

    The proportion of subjects developing donor clonal hematopoiesis

    Measured: 100 days and 365 days post-transplant

  31. Subgroup Analysis of HIV-positive Subjects

    If CCR5delta32 homozygous donors are successfully found and used for one or more HIV-positive subjects, a descriptive analysis of baseline characteristics and outcomes for those HIV-positive subjects will be conducted, including the viral load detected over time obtained from collected samples.

    Measured: 365 days post transplant

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jun 2016 (estimated)
  2. Study startDec 2016
  3. Primary completionMar 2020
  4. Study completionMar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02793544
Sponsor's protocol ID
15-MMUD
Status last verified
Jul 2025
First submitted
31 May 2016
Last updated
6 Aug 2025
Data monitoring committee
Yes

Publications

  • Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolanos-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 Jun 20;39(18):1971-1982. doi: 10.1200/JCO.20.03502. Epub 2021 Apr 27.

    PubMed 33905264

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in